FDA, Cephalon add warnings to Provigil
WASHINGTON The Food and Drug Administration as well as the manufacturer Cephalon has notified healthcare professionals that warnings have been added to the prescribing information for Provigil.
Provigil is used to improve wakefulness in adults with excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder.
The new information includes warnings regarding serious rash, including Stevens-Johnson Syndrome and hypersensitivity reactions, and psychiatric symptoms. Rare cases of serious or life-threatening rash, including toxic epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms have been reported in adults and children in worldwide post marketing experience. Angioedema and multi-organ hypersensitivity reactions have also been reported in post-marketing experience.
Pharma, biotech companies in line of wildfires
SAN DIEGO With the wildfires still blazing in areas across San Diego, such pharma and biotech companies as Pfizer are preparing for closures and even evacuations of some of their facilities, according to drugresearcher.com.
Pfizer’s La Jolla research and development site is a 33.5-acre campus, with facilities covering more than 1 million square feet, including Pfizer’s vaccines research and The Pfizer Incubator, a new facility where the company is financing life science start-ups. The HIV drug Viracept is produced at the site, as well as new treatments for cancer and diseases of the eye.
Across San Diego County, there are more than 500 life science companies employing more than 36,000 people, according to industry association Biocom. The companies range from small biotechs to some of the biggest names in drug development, such as Johnson & Johnson, Bristol-Myers Squibb, Amgen, Biogen Idec, Genentech and Pfizer. Between them, they generate more than $23 million for the economy every day.
Pharmacy OneSource ranks in Deloitte’s top 100
BELLEVUE, Wash. Pharmacy OneSource has been ranked number 84 on Deloitte’s Technology Fast 500, a ranking of the 500 fastest growing technology, media, telecommunications and life sciences companies in North America. The company grew 2011 percent in fiscal revenue from 2002-2006, which was the time period used to measure each company’s ranking.
“We enjoy our strong relationship with pharmacy professionals and the opportunity it brings to stay intimate with their needs,” said Keith Streckenbach, chief strategy officer. “This knowledge, combined with excellent hires, has catalyzed our growth.”
Pharmacy OneSource was also ranked sixth on the Washington State Technology Fast 50, which ranks the 50 fastest growing technology firms in Washington State.